From gene bombs to classroom curriculum
By Svetlana Reiter, Alexander Ershov, and Farida Rustamova,
Meduza
| 04. 14. 2021
Until recently, the Russian authorities showed little interest in genetics. The breakthrough came in 2019, when the government allocated 127 billion rubles ($1.7 billion) to a special seven-year federal program. In fact, as Meduza learned, the Kremlin’s overall spending on projects involving genetics could actually reach 230 billion rubles ($3 billion) in the coming years. Vladimir Putin personally supervises the implementation of these programs, and he’s put his own relatives and closest friends (in particular, his eldest daughter Maria Vorontsova and the cellist Sergey Roldugin) in charge of overseeing the work. Additionally, the oil giant Rosneft acts as the state’s main corporate partner. Meduza explains how the president became infatuated with a field of science that was heresy in the Soviet Union and neglected in the decades after communism’s collapse.
The journal Nature first approached molecular and cell biologist Fyodor Urnov in late 2014, asking him to review new Chinese research on editing human embryos. The experiments horrified the UC Berkeley professor.
“How to formulate this without using profanity… Generally speaking, [the Chinese scientists] promised to use this method to...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...